Table 3.
Clinical baseline characteristics of the KRAS-mutated MSS CRC patients in the GEO cohort
| Characteristics | No. patients | Patients % |
|---|---|---|
| Age, median (range) | 66 (42-83) | |
| Sex | ||
| Female | 5 | 26% |
| Male | 14 | 74% |
| Primary site | ||
| Ascending | 3 | 16% |
| Cecum | 2 | 11% |
| Rectum | 8 | 42% |
| Sigmoid | 6 | 32% |
| Number of metastasis | ||
| 1 | 8 | 42% |
| 2 | 9 | 47% |
| 3 | 2 | 11% |
| Molecular subtype | ||
| CMS2 | 3 | 16% |
| CMS3 | 5 | 26% |
| CMS4 | 11 | 58% |
| Chemotherapy | ||
| FOLFIRI | 1 | 5% |
| FOLFOX | 7 | 37% |
| FOLFOX + Bev | 8 | 42% |
| others | 1 | 5% |
| SOX + Bev | 2 | 11% |
| Anti-EGFR therapy | ||
| Cetuximab | 18 | 95% |
| Panitumumab | 1 | 5% |
MSS: Microsatellite Stable; CRC: Colorectal Cancer; GEO: Gene Expression Omnibus.